Is butyrate the link between diet, intestinal microbiota and obesity-related metabolic diseases?

Obesity Reviews

Volumn 14, Issue 12, 2013, Pages 950-959

  Brahe, L K ^a   Astrup, A ^a   Larsen, L H ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Butyrate; Butyrate producing bacteria; Intestinal microbiota; Obesity related diseases

Indexed keywords

BUTYRIC ACID; C REACTIVE PROTEIN; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; MUCIN 2; OROSOMUCOID; PROPIONIC ACID; TIGHT JUNCTION PROTEIN;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; BACTERIAL CELL WALL; BACTERIAL GROWTH; CALORIC INTAKE; CARBOHYDRATE INTAKE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL RENEWAL; COLON ABSORPTION; COLON FLORA; DIET; ENERGY RESOURCE; EUBACTERIUM; EUBACTERIUM RECTALE; FAECALIBACTERIUM PRAUSNITZII; FECES; GENE EXPRESSION; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTESTINE FLORA; INTESTINE MUCOSA PERMEABILITY; LIPID DIET; LIPID STORAGE; METABOLIC DISORDER; MICROBIAL COMMUNITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN INTAKE; REVIEW; ROSEBURIA INTESTINALIS; STOMACH PH; TIGHT JUNCTION;

BUTYRATE; BUTYRATE-PRODUCING BACTERIA; INTESTINAL MICROBIOTA; OBESITY-RELATED DISEASES;

ANTI-INFLAMMATORY AGENTS; BACTERIA, ANAEROBIC; BUTYRATES; DIET; HUMANS; INTESTINES; METABOLIC DISEASES; MICROBIOTA; OBESITY;

EID: 84887611901     PISSN: 14677881     EISSN: 1467789X     Source Type: Journal    
DOI: 10.1111/obr.12068     Document Type: Review

References (114)

1. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 860-867.
2. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol 2010; 29: 415-445. doi: 10.1146/annurev-immunol-031210-101322.
3. Osborn O, Olefsky JM. The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med 2012; 18: 363-374. doi: 10.1038/nm.2627; 10.1038/nm.2627.
4. Cani PD, Neyrinck AM, Fava F etal. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 2007; 50: 2374-2383. doi: 10.1007/s00125-007-0791-0.
5. Roberfroid M, Gibson GR, Hoyles L etal. Prebiotic effects: metabolic and health benefits. Br J Nutr 2010; 104(Suppl. S2): S1-S63. doi: 10.1017/S0007114510003363.
6. Hakansson A, Molin G. Gut microbiota and inflammation. Nutrients 2011; 3: 637-682. doi: 10.3390/nu3060637.
7. Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota. Nature 2012; 489: 220-230. doi: 10.1038/nature11550.
8. Eckburg PB, Bik EM, Bernstein CN etal. Diversity of the human intestinal microbial flora. Science 2005; 308: 1635-1638. doi: 10.1126/science.1110591.
9. Ley RE, Bäckhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A 2005; 102: 11070-11075. doi: 10.1073/pnas.0504978102.
10. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature 2006; 444: 1022-1023. doi: 10.1038/4441022a.
11. Turnbaugh PJ, Hamady M, Yatsunenko T etal. A core gut microbiome in obese and lean twins. Nature 2009; 457: 480-484. doi: 10.1038/nature07540.
12. Furet JP, Kong LC, Tap J etal. Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes 2010; 59: 3049-3057. doi: 10.2337/db10-0253.
13. Duncan SH, Lobley GE, Holtrop G etal. Human colonic microbiota associated with diet, obesity and weight loss. Int J Obes (Lond) 2008; 32: 1720-1724. doi: 10.1038/ijo.2008.155.
14. Larsen N, Vogensen FK, van den Berg FW etal. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One 2010; 5: e9085. doi: 10.1371/journal.pone.0009085.
15. Patil DP, Dhotre DP, Chavan SG etal. Molecular analysis of gut microbiota in obesity among Indian individuals. J Biosci 2012; 37: 647-657.
16. Arumugam M, Raes J, Pelletier E etal. Enterotypes of the human gut microbiome. Nature 2011; 473: 174-180.
17. Schwiertz A, Taras D, Schafer K etal. Microbiota and SCFA in lean and overweight healthy subjects. Obesity (Silver Spring) 2010; 18: 190-195.
18. Louis P, Flint HJ. Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. FEMS Microbiol Lett 2009; 294: 1-8. doi: 10.1111/j.1574-6968.2009.01514.x.
19. Meijer K, de Vos P, Priebe MG. Butyrate and other short-chain fatty acids as modulators of immunity: what relevance for health? Curr Opin Clin Nutr Metab Care 2010; 13: 715-721. doi: 10.1097/MCO.0b013e32833eebe5.
20. Qin J, Li Y, Cai Z etal. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 2012; 490: 55-60. doi: 10.1038/nature11450.
21. Cummings JH, Pomare EW, Branch WJ, Naylor CP, Macfarlane GT. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut 1987; 28: 1221-1227.
22. Wong JM, de Souza R, Kendall CW, Emam A, Jenkins DJ. Colonic health: fermentation and short chain fatty acids. J Clin Gastroenterol 2006; 40: 235-243.
23. Roy CC, Kien CL, Bouthillier L, Levy E. Short-chain fatty acids: ready for prime time? Nutr Clin Pract 2006; 21: 351-366.
24. Bergman EN. Energy contributions of volatile fatty acids from the gastrointestinal tract in various species. Physiol Rev 1990; 70: 567-590.
25. Vrieze A, Holleman F, Zoetendal EG, de Vos WM, Hoekstra JB, Nieuwdorp M. The environment within: how gut microbiota may influence metabolism and body composition. Diabetologia 2010; 53: 606-613. doi: 10.1007/s00125-010-1662-7.
26. Lin HV, Frassetto A, Kowalik EJ Jr etal. Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. PLoS One 2012; 7: e35240. doi: 10.1371/journal.pone.0035240.
27. Gao Z, Yin J, Zhang J etal. Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes 2009; 58: 1509-1517. doi: 10.2337/db08-1637.
28. Barcenilla A, Pryde SE, Martin JC etal. Phylogenetic relationships of butyrate-producing bacteria from the human gut. Appl Environ Microbiol 2000; 66: 1654-1661.
29. Louis P, Flint HJ. Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. FEMS Microbiol Lett 2009; 294: 1-8. doi: 10.1111/j.1574-6968.2009.01514.x.
30. De Vuyst L, Leroy F. Cross-feeding between bifidobacteria and butyrate-producing colon bacteria explains bifidobacterial competitiveness, butyrate production, and gas production. Int J Food Microbiol 2011; 149: 73-80. doi: 10.1016/j.ijfoodmicro.2011.03.003.
31. Topping DL, Clifton PM. Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiol Rev 2001; 81: 1031-1064.
32. Fava F, Gitau R, Griffin BA, Gibson GR, Tuohy KM, Lovegrove JA. The type and quantity of dietary fat and carbohydrate alter faecal microbiome and short-chain fatty acid excretion in a metabolic syndrome 'at-risk' population. Int J Obes (Lond) 2012; 37: 216-223. doi: 10.1038/ijo.2012.33.
33. Ritzhaupt A, Ellis A, Hosie KB, Shirazi-Beechey SP. The characterization of butyrate transport across pig and human colonic luminal membrane. J Physiol 1998; 507(Pt 3): 819- 830.
34. Gupta N, Martin PM, Prasad PD, Ganapathy V. SLC5A8 (SMCT1)-mediated transport of butyrate forms the basis for the tumor suppressive function of the transporter. Life Sci 2006; 78: 2419-2425. doi: 10.1016/j.lfs.2005.10.028.
35. Musso G, Gambino R, Cassader M. Interactions between gut microbiota and host metabolism predisposing to obesity and diabetes. Annu Rev Med 2011; 62: 361-380. doi: 10.1146/annurev-med-012510-175505.
36. Brown AJ, Goldsworthy SM, Barnes AA etal. The orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem 2003; 278: 11312-11319. doi: 10.1074/jbc.M211609200.
37. Le Poul E, Loison C, Struyf S etal. Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J Biol Chem 2003; 278: 25481-25489. doi: 10.1074/jbc.M301403200.
38. Nilsson NE, Kotarsky K, Owman C, Olde B. Identification of a free fatty acid receptor, FFA2R, expressed on leukocytes and activated by short-chain fatty acids. Biochem Biophys Res Commun 2003; 303: 1047-1052.
39. Tazoe H, Otomo Y, Karaki S etal. Expression of short-chain fatty acid receptor GPR41 in the human colon. Biomed Res 2009; 30: 149-156.
40. Covington DK, Briscoe CA, Brown AJ. Jayawickreme CK. The G-protein-coupled receptor 40 family (GPR40-GPR43) and its role in nutrient sensing. Biochem Soc Trans 2006; 34(Pt 5): 770-773. doi: 10.1042/BST0340770.
41. Maslowski KM, Vieira AT, Ng A etal. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 2009; 461: 1282-1286. doi: 10.1038/nature08530.
42. Ulven T. Short-chain free fatty acid receptors FFA2/GPR43 and FFA3/GPR41 as new potential therapeutic targets. Front Endocrinol (Lausanne) 2012; 3: 111. doi: 10.3389/fendo.2012.00111.
43. Bjursell M, Admyre T, Goransson M etal. Improved glucose control and reduced body fat mass in free fatty acid receptor 2-deficient mice fed a high-fat diet. Am J Physiol Endocrinol Metab 2011; 300: E211-E220. doi: 10.1152/ajpendo.00229.2010.
44. Samuel BS, Shaito A, Motoike T etal. Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. Proc Natl Acad Sci U S A 2008; 105: 16767-16772. doi: 10.1073/pnas.0808567105.
45. Daly K, Shirazi-Beechey SP. Microarray analysis of butyrate regulated genes in colonic epithelial cells. DNA Cell Biol 2006; 25: 49-62. doi: 10.1089/dna.2006.25.49.
46. Brun P, Castagliuolo I, Leo VD etal. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2007; 292: G518-G525. doi: 10.1152/ajpgi.00024.2006.
47. Turner JR. Molecular basis of epithelial barrier regulation: from basic mechanisms to clinical application. Am J Pathol 2006; 169: 1901-1909. doi: 10.2353/ajpath.2006.060681.
48. Ploger S, Stumpff F, Penner GB etal. Microbial butyrate and its role for barrier function in the gastrointestinal tract. Ann N Y Acad Sci 2012; 1258: 52-59. doi: 10.1111/j.1749-6632.2012.06553.x.
49. Wang HB, Wang PY, Wang X, Wan YL, Liu YC. Butyrate enhances intestinal epithelial barrier function via up-regulation of tight junction protein claudin-1 transcription. Dig Dis Sci 2012; 57: 3126-3135. doi: 10.1007/s10620-012-2259-4.
50. Willemsen LE, Koetsier MA, van Deventer SJ, van Tol EA. Short chain fatty acids stimulate epithelial mucin 2 expression through differential effects on prostaglandin E(1) and E(2) production by intestinal myofibroblasts. Gut 2003; 52: 1442-1447.
51. Gaudier E, Rival M, Buisine MP, Robineau I, Hoebler C. Butyrate enemas upregulate muc genes expression but decrease adherent mucus thickness in mice colon. Physiol Res 2009; 58: 111-119.
52. Hamer HM, Jonkers DM, Renes IB etal. Butyrate enemas do not affect human colonic MUC2 and TFF3 expression. Eur J Gastroenterol Hepatol 2010; 22: 1134-1140. doi: 10.1097/MEG.0b013e32833a6ca0.
53. Hamer HM, Jonkers DM, Bast A etal. Butyrate modulates oxidative stress in the colonic mucosa of healthy humans. Clin Nutr 2009; 28: 88-93. doi: 10.1016/j.clnu.2008.11.002.
54. Vanhoutvin SA, Troost FJ, Hamer HM etal. Butyrate-induced transcriptional changes in human colonic mucosa. PLoS One 2009; 4: e6759. doi: 10.1371/journal.pone.0006759.
55. Tappenden KA, Albin DM, Bartholome AL, Mangian HF. Glucagon-like peptide-2 and short-chain fatty acids: a new twist to an old story. J Nutr 2003; 133: 3717-3720.
56. Cani PD, Possemiers S, Van de Wiele T etal. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009; 58: 1091-1103. doi: 10.1136/gut.2008.165886.
57. de Kort S, Keszthelyi D, Masclee AA. Leaky gut and diabetes mellitus: what is the link? Obes Rev 2011; 12: 449-458. doi: 10.1111/j.1467-789X.2010.00845.x.
58. Amar J, Chabo C, Waget A etal. Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. EMBO Mol Med 2011; 3: 559-572. doi: 10.1002/emmm.201100159.
59. Cani PD, Delzenne NM. The gut microbiome as therapeutic target. Pharmacol Ther 2011; 130: 202-212. doi: 10.1016/j.pharmthera.2011.01.012.
60. Ghoshal S, Witta J, Zhong J, de Villiers W, Eckhardt E. Chylomicrons promote intestinal absorption of lipopolysaccharides. J Lipid Res 2009; 50: 90-97. doi: 10.1194/jlr.M800156-JLR200.
61. Bours V, Bonizzi G, Bentires-Alj M etal. NF-kappaB activation in response to toxical and therapeutical agents: role in inflammation and cancer treatment. Toxicology 2000; 153: 27-38.
62. Creely SJ, McTernan PG, Kusminski CM etal. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab 2007; 292: E740-E747. doi: 10.1152/ajpendo.00302.2006.
63. Pussinen PJ, Havulinna AS, Lehto M, Sundvall J, Salomaa V. Endotoxemia is associated with an increased risk of incident diabetes. Diabetes Care 2011; 34: 392-397. doi: 10.2337/dc10-1676.
64. Sun L, Yu Z, Ye X etal. A marker of endotoxemia is associated with obesity and related metabolic disorders in apparently healthy Chinese. Diabetes Care 2010; 33: 1925-1932. doi: 10.2337/dc10-0340.
65. Moreno-Navarrete JM, Ortega F, Serino M etal. Circulating lipopolysaccharide-binding protein (LBP) as a marker of obesity-related insulin resistance. Int J Obes (Lond) 2012; 36: 1442-1449. doi: 10.1038/ijo.2011.256.
66. Romani J, Caixas A, Escote X etal. Lipopolysaccharide-binding protein is increased in patients with psoriasis with metabolic syndrome, and correlates with C-reactive protein. Clin Exp Dermatol 2012; 38: 81-84. doi: 10.1111/ced.12007.
67. Vinolo MA, Rodrigues HG, Festuccia WT etal. Tributyrin attenuates obesity-associated inflammation and insulin resistance in high-fat-fed mice. Am J Physiol Endocrinol Metab 2012; 303: E272-E282. doi: 10.1152/ajpendo.00053.2012.
68. Inan MS, Rasoulpour RJ, Yin L, Hubbard AK, Rosenberg DW, Giardina C. The luminal short-chain fatty acid butyrate modulates NF-kappaB activity in a human colonic epithelial cell line. Gastroenterology 2000; 118: 724-734.
69. Segain JP, Raingeard de la Bletiere D, Bourreille A etal. Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut 2000; 47: 397-403.
70. Luhrs H, Gerke T, Schauber J etal. Cytokine-activated degradation of inhibitory kappaB protein alpha is inhibited by the short-chain fatty acid butyrate. Int J Colorectal Dis 2001; 16: 195-201.
71. Luhrs H, Gerke T, Muller JG etal. Butyrate inhibits NF-kappaB activation in lamina propria macrophages of patients with ulcerative colitis. Scand J Gastroenterol 2002; 37: 458-466.
72. Menzel T, Luhrs H, Zirlik S etal. Butyrate inhibits leukocyte adhesion to endothelial cells via modulation of VCAM-1. Inflamm Bowel Dis 2004; 10: 122-128.
73. Kinoshita M, Suzuki Y, Saito Y. Butyrate reduces colonic paracellular permeability by enhancing PPARgamma activation. Biochem Biophys Res Commun 2002; 293: 827-831. doi: 10.1016/S0006-291X(02)00294-2.
74. Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther 2008; 27: 104-119. doi: 10.1111/j.1365-2036.2007.03562.x.
75. Vrieze A, Van Nood E, Holleman F etal. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012; 143: 913.e7-916.e7. doi: 10.1053/j.gastro.2012.06.031.
76. Sokol H, Pigneur B, Watterlot L etal. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 2008; 105: 16731-16736. doi: 10.1073/pnas.0804812105.
77. Marcil V, Delvin E, Seidman E etal. Modulation of lipid synthesis, apolipoprotein biogenesis, and lipoprotein assembly by butyrate. Am J Physiol Gastrointest Liver Physiol 2002; 283: G340-G346. doi: 10.1152/ajpgi.00440.2001.
78. Marcil V, Delvin E, Garofalo C, Levy E. Butyrate impairs lipid transport by inhibiting microsomal triglyceride transfer protein in caco-2 cells. J Nutr 2003; 133: 2180-2183.
79. Manduteanu I, Simionescu M. Inflammation in atherosclerosis: a cause or a result of vascular disorders? J Cell Mol Med 2012; 16: 1978-1990. doi: 10.1111/j.1582-4934.2012.01552.x.
80. Grummer RR. Effect of feed on the composition of milk fat. J Dairy Sci 1991; 74: 3244-3257. doi: 10.3168/jds.S0022-0302(91)78510-X.
81. Joint FAO/WHO Expert Committee on Food Additives (JECFA). Combined Compendium of Food Additive Specifications. All Specifications Monographs from the 1st to the 65th Meeting (1956-2005). Volume 3: Food Additives P-Z. 1st ed. FAO; 2005.
82. Roda A, Simoni P, Magliulo M etal. A new oral formulation for the release of sodium butyrate in the ileo-cecal region and colon. World J Gastroenterol 2007; 13: 1079-1084.
83. Mortensen PB, Clausen MR. Short-chain fatty acids in the human colon: relation to gastrointestinal health and disease. Scand J Gastroenterol Suppl 1996; 216: 132-148.
84. Englyst HN, Cummings JH. Digestion of the polysaccharides of some cereal foods in the human small intestine. Am J Clin Nutr 1985; 42: 778-787.
85. Robertson MD. Dietary-resistant starch and glucose metabolism. Curr Opin Clin Nutr Metab Care 2012; 15: 362-367. doi: 10.1097/MCO.0b013e3283536931.
86. Martinez I, Kim J, Duffy PR, Schlegel VL, Walter J. Resistant starches types 2 and 4 have differential effects on the composition of the fecal microbiota in human subjects. PLoS One 2010; 5: e15046. doi: 10.1371/journal.pone.0015046.
87. van Munster IP, Tangerman A, Nagengast FM. Effect of resistant starch on colonic fermentation, bile acid metabolism, and mucosal proliferation. Dig Dis Sci 1994; 39: 834-842.
88. Schwiertz A, Lehmann U, Jacobasch G, Blaut M. Influence of resistant starch on the SCFA production and cell counts of butyrate-producing Eubacterium spp. in the human intestine. J Appl Microbiol 2002; 93: 157-162.
89. Walker AW, Ince J, Duncan SH etal. Dominant and diet-responsive groups of bacteria within the human colonic microbiota. ISME J 2011; 5: 220-230. doi: 10.1038/ismej.2010.118.
90. Beards E, Tuohy K, Gibson G. Bacterial, SCFA and gas profiles of a range of food ingredients following in vitro fermentation by human colonic microbiota. Anaerobe 2010; 16: 420-425. doi: 10.1016/j.anaerobe.2010.05.006.
91. Falony G, Vlachou A, Verbrugghe K, De Vuyst L. Cross-feeding between Bifidobacterium longum BB536 and acetate-converting, butyrate-producing colon bacteria during growth on oligofructose. Appl Environ Microbiol 2006; 72: 7835-7841. doi: 10.1128/AEM.01296-06.
92. Tsukahara T, Iwasaki Y, Nakayama K, Ushida K. Stimulation of butyrate production in the large intestine of weaning piglets by dietary fructooligosaccharides and its influence on the histological variables of the large intestinal mucosa. J Nutr Sci Vitaminol (Tokyo) 2003; 49: 414-421.
93. Duncan SH, Scott KP, Ramsay AG etal. Effects of alternative dietary substrates on competition between human colonic bacteria in an anaerobic fermentor system. Appl Environ Microbiol 2003; 69: 1136-1142.
94. Ramirez-Farias C, Slezak K, Fuller Z, Duncan A, Holtrop G, Louis P. Effect of inulin on the human gut microbiota: stimulation of Bifidobacterium adolescentis and Faecalibacterium prausnitzii. Br J Nutr 2009; 101: 541-550. doi: 10.1017/S0007114508019880.
95. Dewulf EM, Cani PD, Claus SP etal. Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. Gut 2013; 62: 1112-1121. doi: 10.1136/gutjnl-2012-303304.
96. Belenguer A, Duncan SH, Calder AG etal. Two routes of metabolic cross-feeding between Bifidobacterium adolescentis and butyrate-producing anaerobes from the human gut. Appl Environ Microbiol 2006; 72: 3593-3599. doi: 10.1128/AEM.72.5.3593-3599.2006.
97. Louis P, Scott KP, Duncan SH, Flint HJ. Understanding the effects of diet on bacterial metabolism in the large intestine. J Appl Microbiol 2007; 102: 1197-1208. doi: 10.1111/j.1365-2672.2007.03322.x.
98. Al-Tamimi EK, Seib PA, Snyder BS, Haub MD. Consumption of cross-linked resistant starch (RS4(XL)) on glucose and insulin responses in humans. J Nutr Metab 2010; 2010: 1-6. doi: 10.1155/2010/651063.
99. Bodinham CL, Frost GS, Robertson MD. Acute ingestion of resistant starch reduces food intake in healthy adults. Br J Nutr 2010; 103: 917-922. doi: 10.1017/S0007114509992534.
100. Cummings JH, Macfarlane GT. The control and consequences of bacterial fermentation in the human colon. J Appl Bacteriol 1991; 70: 443-459.
101. Walker AW, Duncan SH, McWilliam Leitch EC, Child MW, Flint HJ. pH and peptide supply can radically alter bacterial populations and short-chain fatty acid ratios within microbial communities from the human colon. Appl Environ Microbiol 2005; 71: 3692-3700. doi: 10.1128/AEM.71.7.3692-3700.2005.
102. Duncan SH, Belenguer A, Holtrop G, Johnstone AM, Flint HJ, Lobley GE. Reduced dietary intake of carbohydrates by obese subjects results in decreased concentrations of butyrate and butyrate-producing bacteria in feces. Appl Environ Microbiol 2007; 73: 1073-1078. doi: 10.1128/AEM.02340-06.
103. Due A, Toubro S, Skov AR, Astrup A. Effect of normal-fat diets, either medium or high in protein, on body weight in overweight subjects: a randomised 1-year trial. Int J Obes Relat Metab Disord 2004; 28: 1283-1290. doi: 10.1038/sj.ijo.0802767.
104. Larsen TM, Dalskov SM, van Baak M etal. Diets with high or low protein content and glycemic index for weight-loss maintenance. N Engl J Med 2010; 363: 2102-2113. doi: 10.1056/NEJMoa1007137.
105. Windey K, De Preter V, Verbeke K. Relevance of protein fermentation to gut health. Mol Nutr Food Res 2012; 56: 184-196. doi: 10.1002/mnfr.201100542.
106. Russell WR, Gratz SW, Duncan SH etal. High-protein, reduced-carbohydrate weight-loss diets promote metabolite profiles likely to be detrimental to colonic health. Am J Clin Nutr 2011; 93: 1062-1072. doi: 10.3945/ajcn.110.002188.
107. Bajka BH, Clarke JM, Cobiac L, Topping DL. Butyrylated starch protects colonocyte DNA against dietary protein-induced damage in rats. Carcinogenesis 2008; 29: 2169-2174. doi: 10.1093/carcin/bgn173.
108. Cani PD, Amar J, Iglesias MA etal. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007; 56: 1761-1772. doi: 10.2337/db06-1491.
109. Erridge C, Attina T, Spickett CM, Webb DJ. A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr 2007; 86: 1286-1292.
110. Amar J, Burcelin R, Ruidavets JB etal. Energy intake is associated with endotoxemia in apparently healthy men. Am J Clin Nutr 2008; 87: 1219-1223.
111. Ghanim H, Abuaysheh S, Sia CL etal. Increase in plasma endotoxin concentrations and the expression of toll-like receptors and suppressor of cytokine signaling-3 in mononuclear cells after a high-fat, high-carbohydrate meal: implications for insulin resistance. Diabetes Care 2009; 32: 2281-2287. doi: 10.2337/dc09-0979.
112. Deopurkar R, Ghanim H, Friedman J etal. Differential effects of cream, glucose, and orange juice on inflammation, endotoxin, and the expression of toll-like receptor-4 and suppressor of cytokine signaling-3. Diabetes Care 2010; 33: 991-997. doi: 10.2337/dc09-1630.
113. Rabot S, Membrez M, Bruneau A etal. Germ-free C57BL/6J mice are resistant to high-fat-diet-induced insulin resistance and have altered cholesterol metabolism. FASEB J 2010; 24: 4948-4959. doi: 10.1096/fj.10-164921.
114. Neyrinck AM, Possemiers S, Verstraete W, De Backer F, Cani PD, Delzenne NM. Dietary modulation of clostridial cluster XIVa gut bacteria (Roseburia spp.) by chitin-glucan fiber improves host metabolic alterations induced by high-fat diet in mice. J Nutr Biochem 2012; 23: 51-59. doi: 10.1016/j.jnutbio.2010.10.008.